EyePoint Pharmaceuticals (EYPT)
(Delayed Data from NSDQ)
$10.23 USD
+0.16 (1.59%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $10.23 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
EYEPOINT PHARMACEUTICALS, INC.'s return on equity, or ROE, is -61.64% compared to the ROE of the Medical - Biomedical and Genetics industry of -61.64%. While this shows that EYPT has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
EYPT 10.23 +0.16(1.59%)
Will EYPT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for EYPT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EYPT
EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates
Guardant Health (GH) Reports Q2 Loss, Beats Revenue Estimates
EYPT: What are Zacks experts saying now?
Zacks Private Portfolio Services
EyePoint Pharmaceuticals (EYPT) Reports Q1 Earnings: What Key Metrics Have to Say
EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Tops Revenue Estimates
EyePoint Pharmaceuticals (EYPT) Reports Q4 Earnings: What Key Metrics Have to Say
Other News for EYPT
EyePoint Pharmaceuticals (EYPT): Chardan Capital Maintains "Buy" Rating | EYPT Stock News
EyePoint Pharmaceuticals (EYPT) Receives Updated Analyst Ratings | EYPT Stock News
Q2 2025 EyePoint Pharmaceuticals Inc Earnings Call Transcript
EyePoint price target raised by $1 at H.C. Wainwright, here's why
EyePoint to Present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference | EYPT ...